Levoferin

There is no image.

Levodropropizine

Method of action: Antitussive, Cough And Cold Preparations

Treatment option: Bronchitis, Influenza, Cough, Laryngitis, Pharyngitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levoferin

Quick Facts

Property	Description
Active ingredient	Levodropropizine
Pharmacological class	Antitussive agent (Cough suppressant)
Origin	Synthetic, S-enantiomer
Site of action	Peripheral (airways and nerve endings)
Forms	Oral syrup, tablets, drops, capsules
Common use	Symptomatic relief of non-productive (dry) cough

What is Levoferin? Definition and Identity

Levoferin is a pharmaceutical preparation whose primary role is to act as a non-opioid antitussive agent, designed to provide symptomatic relief from an unproductive (dry) cough. Its active ingredient is Levodropropizine, a synthetic compound recognized by the World Health Organization (WHO) with the ATC code R05DB27 (Other cough suppressants). This classification establishes the drug's specialized function in respiratory medicine, which is clinically recognized for its efficacy in controlling irritation leading to dry cough.

Composition, Class, and Purpose

Levodropropizine is defined by its class as a peripheral antitussive, a key differentiator that ensures it exerts its primary suppressive action on the sensory nerve endings in the airways, rather than on the central nervous system (CNS). This non-narcotic approach is highly valued, as pharmacological studies confirm the compound achieves its therapeutic effect without the central depressive effects often associated with older, opioid-derived suppressants. The product is typically a single-active ingredient product where the Levodropropizine is combined with a base appropriate for the form. The main purpose remains the consistent, localized calming of the cough reflex, used in scenarios where persistent, non-productive coughing affects quality of life.

Available Forms and Administration Type

The active ingredient, Levodropropizine, is manufactured for oral consumption in several different dosage forms, ensuring versatility in treatment. These commonly include oral syrup, oral tablets, oral drops, and occasionally oral capsules. The availability of liquid forms, such as the syrup and drops, is particularly important as it facilitates accurate and easy oral administration for the pediatric population (children over two years old). This range of available presentations confirms the drug's utility in managing dry cough for both adults and children.

What side effects are possible with Levoferin?

Possible side effects and safety information

Levoferin (Levodropropizine) has a documented safety profile derived from clinical studies and post-marketing surveillance, classified according to governmental regulatory standards. The adverse reactions are formally categorized by frequency and the physiological systems affected.

Adverse Reaction Classification

The most frequently observed adverse reactions are classified as Common, typically involving Gastro-intestinal disorders (such as nausea, vomiting, heartburn, and dyspepsia) and the Nervous system (including somnolence and vertigo). Reactions are also documented across other systems, including the skin, cardiac, and immune systems.

Classification	System-Organ Class Examples
Common	Nausea, Vomiting, Somnolence, Vertigo
Very Rare	Anaphylaxis, Seizures, Cardiac Arrhythmia

Serious Adverse Reactions

Official labeling documents the occurrence of Serious Adverse Reactions, generally classified as Very Rare or reported as Isolated Cases. These include events such as anaphylactic reactions, tonic-clonic convulsions, syncope, cholestatic hepatitis, and rare reports of epidermolysis.

Population-Specific Safety Constraints

The regulatory safety profile defines specific contraindications based on patient health status or physiological state:

Contraindicated: The medicine is not for use in individuals with severe hepatic impairment, bronchorrhea, impaired muco-ciliary function, or during pregnancy and lactation.
Caution is Advised: Special consideration is required for elderly patients and those with severe renal impairment (creatinine clearance below 35 mL/ min).

Furthermore, caution is advised concerning the ability to drive or operate machines due to the possibility of central nervous system effects such as sleepiness, and there is a note about the potential to enhance the effects of other CNS depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Levoferin (Levodropropizine) strictly defines the approach required in the event of an overdose, which must be managed through immediate, supportive care.

Documented Overdose Manifestations

An overdose may be associated with certain documented clinical signs, including the expected occurrence of temporary transitional tachycardia (a brief, rapid heart rate). Furthermore, specific symptoms such as abdominal pain and vomiting have been recorded in a documented pediatric overdose case.

Required Emergency Action

In any instance of suspected overdose or upon the manifestation of evident clinical signs, individuals are required to seek medical attention immediately. The regulatory guidance states that no specific antidote is known for Levodropropizine; therefore, management is strictly supportive.

Immediate response measures described in regulatory documents include the provision of symptomatic and supportive therapies. Specific procedural steps that may be adopted are the administration of gastric lavage, activated charcoal, and parenteral fluid.

Monitoring Focus

During management, special attention is mandated to key physiological systems due to potential effects. This includes continuous monitoring of cardiac, respiratory, renal, and hepatic functions, as well as the maintenance of fluid and electrolytic balance. These actions align with the general measures applied in cases of drug overdose as directed by regulatory authorities.

Therapeutic Uses of Levoferin

What Levoferin Treats: Main Uses and Benefits

Levoferin (Levodropropizine) is a medication generally used for providing supportive relief from specific types of coughs and the associated symptoms related to physical discomfort. The medication plays a role in managing manifestations that create noticeable physiological strain. This drug is considered relevant for the management of non-productive, disturbing cough.

Symptom Management and Therapeutic Scope

Levoferin is commonly used in situations involving certain distressing symptoms of an irritative, non-productive cough. This includes symptoms related to inflammatory or irritative states often seen in conditions associated with acute bronchitis and upper respiratory tract infections. It is relevant when short-term symptomatic assistance is needed to address symptom clusters that interfere with daily comfort, such as excessive coughing that disrupts rest and conversation.

This supports the patient during difficult episodes by easing distress related to the cough's intensity and frequency. “The medication is applied across domains where additional symptomatic support is needed.” This assists with maintaining functional stability and supports the patient, which may help with rest during the symptomatic phase. It is applicable for both adults and the pediatric population (children over two years old) when supportive symptom management is appropriate.

Quick Fact: Relief for Irritative Cough

Property	Description
Primary Focus	Irritative, non-productive dry cough.
Key Benefit	Supports easing discomfort associated with cough intensity and frequency.
Context	Acute episodes of URTIs or bronchitis-related cough.
Patient Groups	Adults and pediatric patients (over two years old).

Eligibility and Restrictions for Use

Levoferin (levodropropizine) is an antitussive medicine whose eligibility for use is defined by specific official contraindications and patient characteristics.

Eligibility and Exclusion Criteria

Classification	Populations Covered
Eligible for Use	Adults and children over 2 years of age.
Contraindicated	Children below 2 years of age; pregnant and lactating women.
Contraindicated	Patients with known hypersensitivity to levodropropizine or any of the product's excipients.
Contraindicated	Patients with excessive mucus discharge (bronchorrhea) or limited mucociliary function (e.g., Kartagener syndrome).
Use with Caution	Patients with severe renal impairment (creatinine clearance < 35 mL/min).

Official regulatory information restricts the use of this medicine to those aged two years and older. The presence of physiological states such as pregnancy or lactation, or conditions like excessive bronchial secretion and severely reduced liver or kidney function (in some official documents) are absolute exclusions for treatment. Use is also strictly prohibited if a patient has any known allergy to the active substance or components like parabens.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Levoferin (Levodropropizine) outlines interaction potential primarily through pharmacodynamic effects. Regulatory documents do not classify any specific medicinal product combination as formally contraindicated. The profile highlights two main categories of constraints: additive central nervous system effects and a mandatory administration timing rule.

Documented Interaction Profile

Interaction Type	Interacting Substance/Agent	Official Constraint/Outcome
Pharmacodynamic	Sedative Drugs (CNS Depressants)	Caution is necessary in particularly sensitive subjects due to the potential for additive or enhanced sedative effects.
Drug-Substance	Alcohol	Avoidance is advised, as consumption may potentiate the risk of adverse effects such as drowsiness, aligning with the sedative caution.
Administration Timing	Food	The product must be administered away from meals because data on the effect of food on drug absorption are absent from the regulatory profile.

Regulatory Summary

The official interaction summaries do not document any significant interactions mediated by the cytochrome P450 enzyme system or drug transporters. Clinical studies confirm the absence of interaction with commonly used medicines for bronchopulmonary diseases, including beta-2-agonists and antibiotics. This regulatory structure defines the constraints on co-administration solely based on the risk of additive central nervous system depression, particularly in sensitive individuals.

Mechanism of Action

Modulation of Airway Sensory Receptors

Levoferin acts peripherally by targeting the afferent pathways of the cough reflex within the tracheobronchial tree. Its primary interaction occurs at sensory nerve endings, where it engages mechanisms that inhibit the excitability of cough-triggering sensory neurons. This includes acting as an inhibitor on Transient Receptor Potential Vanilloid 1 (TRPV1) channels, which are voltage-gated ion channels involved in transmitting nociceptive signals. This interaction modifies early molecular steps in the cough cascade, contributing to a reduction in afferent nerve activity by decreasing the initial sensory signal transmission.

Influence on Neurotransmitter Signaling

Beyond receptor modulation, the drug interferes with local chemical signaling. It initiates a sequence that suppresses the release of sensory neuropeptides, notably Substance P, from C-fibers in the respiratory tract. This modulates key pathways associated with heightened nerve signaling. The resulting decrease in neuropeptide release decreases the sensitivity of the afferent cough pathways, resulting in the modification of afferent signal transmission without acting centrally.

Dosage and Administration Information

How to Use Levoferin

The use of Levoferin (Levodropropizine) is guided by standardized instructions focusing on the approved method and dosage limits. The medication is intended strictly for oral administration and is supplied in various forms, including syrup and drops. For accurate dosing of the liquid forms, a calibrated dosing device must be utilized.

Standard Dosing and Schedule

The standard adult dose is 60 mg per administration. This dose is taken up to three times daily, meaning the total intake should not exceed 180 mg in a 24-hour period. To maintain consistency, a minimum interval of 6 hours is required between each dose. The drug is preferably consumed away from meals or on an empty stomach.

Course Duration and Age-Specific Use

Levoferin is used as a short-term course and should not be taken for more than 7 consecutive days without consulting a healthcare professional for reassessment. For the pediatric population aged 2 years and older, the required dose is determined on a body weight basis, generally calculated between 1 mg/kg and 2 mg/kg up to three times per day. The product is not recommended or contraindicated for use in children under 2 years of age. If a dose is missed, it should be taken as soon as it is remembered, unless the next dose is due within the 6-hour minimum interval, in which case the missed dose should be skipped to avoid exceeding the recommended limit.

Recent Clinical Evidence

Research evidence / Overview of studies for Levoferin

Evidence for Symptomatic Cough in Acute Respiratory Conditions

Research exploring Levoferin (Levodropropizine) was studied for its use in conditions associated with acute, non-productive cough, such as those related to Upper Respiratory Tract Infections (URTIs) and acute bronchitis. This area of study includes multiple Systematic Reviews and Meta-analyses that combine results from many trials. Researchers used short-term Randomized Controlled Trials (RCTs) to monitor how symptoms change over time when compared to inactive treatments (placebo) and other cough preparations.

These studies focused on several key outcomes reflecting daily functioning and patient-reported discomfort. Research examined symptom intensity or variability by measuring the change in cough frequency and severity scores reported by patients. Trials also explored changes in nightly rest by monitoring nocturnal awakenings associated with coughing. Findings from the aggregated meta-analyses describe consistent patterns observed in these measured outcomes during the short-term study periods. The measured outcomes apply only to the populations studied and only for short durations.

Research in Adults and the Pediatric Population

Research has been conducted across both adult and pediatric populations (children over two years old), addressing the use of Levoferin for conditions involving periods of heightened symptoms. Trials monitored outcomes reflecting daily functioning for both groups, with most of the extensive data being derived from the adult population. However, the number of clinical trials involving children is smaller than those involving adults. The available data for the pediatric group are still emerging, and data for certain subgroups within the pediatric range remain insufficient.

Understanding the Research Gaps and Uncertainties

The existing evidence base primarily reflects research exploring short-term symptom changes, typically not exceeding seven days. The limited information for long-term outcomes means the effects of the medicine beyond the resolution of the acute episode are not fully established. Furthermore, evidence is limited regarding the use of the drug in certain chronic cough conditions and specialized populations, with existing studies providing limited insight due to small sample sizes and methodological weaknesses.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Levoferin (FAQ)

Q: What is Levoferin and what is it used for?

A: Levoferin is a prescription medication. It is approved by regulatory bodies for specific indications, which are medical conditions it is intended to treat. The approved use is typically detailed in the official prescribing information provided by the manufacturer.

Q: How does Levoferin work in the body?

A: Research suggests that Levoferin may exert its effects by interacting with certain pathways or receptors in the body. Preliminary findings from preclinical and early-stage studies have explored its potential molecular targets, but this is a complex area of ongoing study.

Q: What clinical evidence supports the use of Levoferin?

A: The approval of Levoferin is supported by data gathered from clinical trials. These studies, which include randomized controlled trials (RCTs), observed various outcomes such as changes in specific symptoms or disease markers. For example, some studies observed that patients receiving Levoferin had a mean change in Symptom Score X compared to the control group. The complete body of evidence is detailed in the official regulatory documents.

Q: Are there common or expected effects when taking Levoferin?

A: Like all medications, Levoferin may be associated with side effects. Clinical trials are conducted to track and document the frequency and nature of these effects. Common observations reported in study populations may include headache, mild nausea, and fatigue. The full list of observed adverse events is available in the medication's official information.

Q: Can Levoferin be taken with other medications?

A: The potential for drug interactions is a significant consideration. Levoferin may interact with certain other prescription and non-prescription medications, herbal supplements, or vitamins. It is essential to consult a healthcare provider to review the complete medication profile and determine if any potentially significant interactions are present.

Q: Who should not take Levoferin?

A: There are specific patient populations for whom Levoferin may not be appropriate. Contraindications, or reasons to avoid the medication, are based on pre-existing medical conditions or known sensitivities. For example, the medication is contraindicated for individuals with a known hypersensitivity to the active ingredient. This critical information is outlined in the official prescribing documentation.

How should Levoferin be stored and disposed of?

Storage Conditions and Requirements

Levoferin (Levodropropizine) must be stored at controlled room temperature, specifically not exceeding 30 C, and must be protected from light. To maintain product integrity and stability, the medicine must be kept in the original bottle pack.

Stability and Child Safety

For the oral solution/syrup form, stability is limited after opening; the product must be discarded after 1 month of first use. A mandatory requirement across all official labeling is to keep the product out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance requires that any unused or expired Levoferin product be disposed of in line with local requirements. Patients are explicitly instructed not to throw away any medicines via wastewater or household waste, and should consult a pharmacist for appropriate disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Peru

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z